anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Approximately 10% of emergency medical services (EMS) encounters in the United States are behavioral health related, but pediatric behavioral health EMS encounters have not been well characterized. We sought to describe demographic, clinical, and EMS system characteristics of pediatric behavioral health EMS encounters across the United States and to evaluate factors associated with sedative medication administration and physical restraint use during these encounters.
METHODS: We conducted a retrospective cross-sectional study of pediatric (<18 years old) behavioral health EMS encounters from 2019 to 2020 using the National Emergency Medical Services Information System. Behavioral health encounters were defined using primary or secondary impression codes. We used multivariable logistic regression to identify factors associated with sedative medication administration and physical restraint use.
RESULTS: Of 2,740,271 pediatric EMS encounters, 309,442 (11.3%) were for behavioral health. Of pediatric behavioral health EMS encounters, 85.2% of patients were 12-17 years old, 57.3% of patients were female, and 86.6% of encounters occurred in urban areas. Sedative medications and physical restraints were used in 2.2% and 3.0% of pediatric behavioral health EMS encounters, respectively. Sedative medication use was associated with the presence of developmental, communication, or physical disabilities relative to their absence (adjusted odds ratio [aOR] 3.38, 95% confidence interval [CI] 2.93-3.91) and with encounters in the West relative to the South (aOR 1.23, 95% CI 1.16-1.32). Physical restraint use was associated with encounters by patients 6-11 years old relative to those 12-17 years old (aOR 1.35, 95% CI 1.27-1.44), the West relative to the South (aOR 3.49, 95% CI 3.27-3.72), and private nonhospital EMS systems relative to fire departments (aOR 3.39, 95% CI 3.18-3.61).
CONCLUSIONS: Among pediatric prehospital behavioral health EMS encounters, the use of sedative medications and physical restraint varies by demographic, clinical, and EMS system characteristics. Regional variation suggests opportunities may be available to standardize documentation and care practices during pediatric behavioral health EMS encounters.
1431092 Lubricating compositions KIMBEBLY CLARK CORP 10 April 1973 17265/73 Heading C3F [Also in Division A5] A solid lubricating composition comprises water-soluble hydroxypropyl cellulose blended with a compatible polyalkylene glycol plasticizer, and having an oleaginous lubricant dispersed throughout. Globules of the lubricant occur on the surface of the composition, some of them uniting to form a film of lubricant. The preferred plasticizers are polyethylene glycol having a molecular weight of from 200 to 1500 and polypropylene glycol having an average molecular weight of less than 750. The lubricants disclosed are glycerine, natural and synthetic fats which are liquid at room temperature, mineral oil and polypropylene glycol having an average molecular weight of at least 1000. The composition is best made by adding the lubricant to hot plasticizer and then adding the hydroxypropyl cellulose, heating some more to obtain a clear solution and then cooling. Consequently it is preferred that the lubricant and plasticizer be compatible or, at least, mutually dispersible at high temperature but incompatible at room temperature. The compositions are intended for medicinal purposes, in particular for making suppositories, and antifungal or bacteriostatic agents and antibiotics may be added. Specified materials are menthol, camphor, quaternary ammonium salts, phenylmercuric nitrate, ephedrine sulphate, benzocain, oxyquinoline benzoate, hexetidine, chloramphenicol, myraldact, aloponone, nystatin, acetarsone, nitrofurazan, benzalkonium chloride and hexachlorophene.
BACKGROUND: Diagnostic accuracy in acute appendicitis (AA) may be improved by using inflammatory markers. This study assessed the reliability of inflammatory markers in diagnosing AA in our patient population.
METHODS: A retrospective cross-sectional study was conducted at King Edward Hospital (KEH) from January 2020 to June 2021. Data was collected on all patients with AA who underwent appendicectomy. Variables of age, gender, comorbidities, HIV status Alvarado score histology, C-reactive protein (CRP), and white cell count (WCC) were reviewed. A p-value of < 0.05 is deemed as statistically significant.
RESULTS: The study cohort was comprised of 150 patients - 58(39%) females and 92(61%) males. Thirty-two (21.3%) patients had a normal appendix, of whom 19 had a normal WCC. The majority of patients 80 (53.3%) had inflamed appendix, and 38 (25.3%) had ruptured appendix. The sensitivity and specificity of WCC and the CRP were 81% and 46% and 100% and 18.6% respectively. No patient with a ruptured appendix had normal CRP. The CRP correlated with the ruptured appendix with a median of 141.5 and, p-value of 0.01. The level of WCC and the presence of a ruptured appendix had a significant correlation with a p-value of 0.002, median of 15.2.
CONCLUSION: A combination of WCC and CRP tests improves the diagnostic accuracy. There is a correlation between CRP level and ruptured appendicitis. In our setting, AA is likely to present late once it has already ruptured. The reasons behind this late presentation need to be explored and addressed.
PURPOSE:An anticancer agent consisting of a glycoprotein consisting essentially of xylose in cultivated mycelia belonging to basidiomycetes, e.g. SHIITAKE mushroom, cultivated in a specific culture medium. CONSTITUTION:An anticancer agent, consisting of a glycoprotein consisting essentially of xylose, and obtained from cultivated mycelia belonging to basidiomycetes, e.g. SHIITAKE mushroom, cultivated in a solid culture medium rich in the xylose component. Pleurotus ostreatus Quel., Flammalina velutipes Sing., Lyophyllum aggregatum and Pholiota nameko, in addition to the SHIITAKE mushroom may be cited as the basidiomycetes. A mixture of 90% pulverized bagasse with 5% rice bran, 5% nutriment, e.g. bran, is used as the solid culture medium. The bagasse is easily available at a low cost.
The disclosure relates to a method and a system for a wireless data communication between a sensor system and a receiver capable of receiving analyte values sensed by the sensor system in a continuous analyte monitoring. The method includes establishing an unconnected mode operation for the system. The receiver receives a first data package broadcasted by the sensor system that has first status data indicative of a device status and/or an analyte value status. The first status data is processed by a receiver controller. A connected mode operation is established for the system responsive to determining at least one of a critical device status and a critical analyte value status. The establishing includes establishing a communication channel between the sensor system and the receiver and receiving a second data package transmitted by the sensor system in the receiver, the second data package comprising one or more analyte values.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by swelling in at least one joint. Owing to an overactive immune response, extra-articular manifestations are observed in certain cases, with interstitial lung disease (ILD) being the most common. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is characterized by chronic inflammation of the interstitial space, which causes fibrosis and the scarring of lung tissue. Controlling inflammation and pulmonary fibrosis in RA-ILD is important because they are associated with high morbidity and mortality. Pirfenidone and nintedanib are specific drugs against idiopathic pulmonary fibrosis and showed efficacy against RA-ILD in several clinical trials. Immunosuppressants and disease-modifying antirheumatic drugs (DMARDs) with anti-fibrotic effects have also been used to treat RA-ILD. Immunosuppressants moderate the overexpression of cytokines and immune cells to reduce pulmonary damage and slow the progression of fibrosis. DMARDs with mild anti-fibrotic effects target specific fibrotic pathways to regulate fibrogenic cellular activity, extracellular matrix homeostasis, and oxidative stress levels. Therefore, specific medications are required to effectively treat RA-ILD. In this review, the commonly used RA-ILD treatments are discussed based on their molecular mechanisms and clinical trial results. In addition, a computational approach is proposed to develop specific drugs for RA-ILD.
PROBLEM TO BE SOLVED: To address the problem that fundamental treatment with medicine is difficult and that there is no fundamental treatment other than resection of the infected area etc. by surgery of fistula which is caused by bacterial infection, as bacteria is supplied almost every day by defecation to a small indentation (anal crypt) which is the entry port of bacteria about 2 cm from the anal margin (exit of feces) or the infected part of the anal gland which produces pus which is inside the anus, provided is a therapeutic agent that can be expected to suppress the symptoms of fistula by the continuous application thereof, due to the composition of the therapeutic agent being excellent in strong bactericidal and antibacterial action etc.MEANS: Juice from astringent persimmon grated with a grater is wrapped in gauze and squeezed into a container. The therapeutic agent is made by submerging granules of Seirogan which are commercially available into the juice or submerging leaves of Dokudami washed with tap water lightly and rubbed with fingertips, into the juice. Usage thereof is continued once or twice a day, after bathing or after defecation, after washing the anus with a washlet or tap water, a cotton bud is used to apply the therapeutic agent to the pus discharging fissure etc. for about 6 months. An approximately 50 g container can be used for equal to or more than 6 months.SELECTED DRAWING: Figure 6
Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Cell-targeted cytotoxic compounds are provided herein. Such compounds can be used,  e.g. , to selectively bind and kill cancer cells such as cancer stem cells that express LGR4, LGR5, or LGR6. In some embodiments, the cytotoxic compounds include an LGR binding polypeptide, a cytotoxic agent ( e.g. , MMAE), and an Fc region ( e.g. , a mutant Fc domain). Methods for using the compounds to treat cell proliferative diseases such as cancers are also provided.
This arm includes the use of benzodiazepines (Diazepam or Lorazepam) when CIWA-Ar scale is ≥9. Other medications may include Thiamine, Potassium Chloride, oral rehydration salts, parenteral fluids, antiemetics, and gastric protectants if medically necessary. Patients undergo a psychological evaluation on the third day of admission. All patients receive at least one psychoeducational session on alcohol and substance use during their hospitalization. Psychiatric evaluation is available for those with dual diagnoses such as mood disorders, anxiety disorders, psychotic disorders, or multiple substance use. The total hospitalization time in the ward is 8 days.
Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
FIELD: pharmaceutics. SUBSTANCE: it is conducted a step-by-step mixing of trimetoprime with additional substances - pre-prepared mixture of starch and milk sugar, and then - with sulfametoxasole. The mixture obtained is impregnated with granulating liquid as 10% polyvinylpyrrolidone aqueous solution at 25000-40000 molecular weight. Then comes damp granulation, drying, dry granulation, powdering due to successive mixing of dry granulate with reduced substandard tablets and calcium stearate, and tabletting. The method enables to utilize substandard production, introduce a substance which softens the taste of a tablet due to decreased number of additional substances along with keeping both integrity and decomposition capacity of a tablet. The tablets are very useful in treating infections of respiratory, urinary and gastrointestinal tracts, surgical infection and other infectious diseases. EFFECT: higher efficiency.
In December of 2019, a previously unknown betacoronavirus was discovered in the airways of patients with pneumonia in Wuhan, China. The novel coronavirus disease (COVID-19) caused by the virus (severe acute respiratory syndrome coronavirus (SARS-CoV-2)) spread rapidly around the world. Common symptoms include cough, fever, dyspnea (i.e. shortness of breath), musculoskeletal aches and pains and fatigue. These symptoms, most notably fatigue and dyspnea, have been reported months after the onset of the disease and often long after patients are thought to have recovered from the disease. Between one and two thirds of patients with milder forms of the disease report symptoms up to two months after the onset of symptoms. This condition is now referred to as Long COVID or Post- Acute Sequelae of SARS-CoV-2 infection, and the characteristic symptoms of this condition are dyspnea and extreme fatigue. Additionally, pulmonary, musculoskeletal, neurological, cardiac, and psychological sequelae in these survivors can affect their physical function and ability to perform activities of daily living. While exercise rehabilitation in patients recovering from COVID-19 has been cautiously recommended, there is little known about the response to exercise in patients with Long COVID-19 nor the optimal methods or strategies for rehabilitating these patients. Understanding the responses to an exercise program is instrumental in designing safe and effective rehabilitation strategies for these patients. The objective of this study is to examine the effect of a 3-month exercise therapy program on physical function in individuals who have recovered from COVID-19 between the previous 2 to 6 months, yet still report symptoms of the disease. The study is a randomized, wait-list-control pilot study designed to gather preliminary data. Participants will be randomized into one of two groups: an immediate treatment group or a wait-list-control group. The immediate treatment group will begin the exercise therapy program following randomization and will participate in the exercise program for a duration of three months. The wait-list-control group will receive usual care for the first three months, after which they will be allowed the opportunity to participate in the exercise therapy program for three months. Outcome measures will me made prior to randomization and following either the three-month exercise program or three months of usual care.
Cancer and related disorders are the most common cause of cancer-related mortality with the incidence of 1 in 9 among the pre-menopausal Pakistani females. among the most common ailments worldwide, indicating the importance of developing particular techniques that could help attenuate the effects of breast cancer and related outcomes. The primary aim of the current study was to review the role of inflammatory and stress markers in the development and progression of breast cancer. Four hundred ninety-eight (n = 498) patients with breast cancer and four hundred and ninety-eight (n = 498) age- and sex-matched controls were selected for this case‒control study. Serum samples were obtained, and the levels of stress and inflammatory markers, including Matrix metalloproteases (MMPs), Interleukins (ILs), Heat shock proteins (HSPs), Malondialdehyde (MDA), Nitric Oxide (NO), inducible Nitric Oxide Synthase (iNOS) and Tumour necrosis factor-alpha (TNF-α), were determined. Most (62%) patients had metastatic breast cancer (stage III or IV) with an adverse grade (65% with Grade III and 35% with Grade II). The present study showed that the levels of oxidants such as MDA, ILs, MMPs and HSPs were significantly greater, while the levels of antioxidants such as Superoxide Dismutase (SOD), Glutathione (GSH), Catalase (CAT), vitamin A, C and D were significantly lower in breast cancer patients than in controls, suggesting their diagnostic importance and role in the pathophysiology of breast cancer. Oxidants, including IL-1, HSP27 and MMP9, which are highly specific and sensitive, may be used to develop the pathophysiological pathways of metastatic breast cancer in these patients. These pathways include cell invasion, cell migration and epithelial-mesenchymal transition. Therefore, we concluded that an increase in growth factors, e.g., Vascular Endothelial Growth Factor (VEGF), Tumour Growth Factor-beta (TGF-β) and B-cell lymphoma (Bcl2), under the influence of these variables plays a crucial role in the metastasis of breast cancer.
Breast cancer represents the most prevalent form of cancer and the leading cause of cancer-related mortality among females worldwide. It has been reported that several risk factors contribute to the appearance and progression of this disease. Despite the advancements in breast cancer treatment, a significant portion of patients with distant metastases still experiences no cure. The extracellular matrix represents a potential target for enhanced serum biomarkers in breast cancer. Furthermore, extracellular matrix degradation and epithelial-mesenchymal transition constitute the primary stages of local invasion during tumorigenesis. Additionally, the microbiome has a potential influence on diverse physiological processes. It is emerging that microbial dysbiosis is a significant element in the development and progression of various cancers, including breast cancer. Thus, a better understanding of extracellular matrix and microbiome interactions could provide novel alternatives to breast cancer treatment and management. In this review, we summarize the current evidence regarding the intricate relationship between breast cancer with the extracellular matrix and the microbiome. We discuss the arising associations and future perspectives in this field.
The present invention provides a mouse/human heterohybrid cell line useful as a fusion partner with B-lymphocytes producing antibody to an antigen of interest collected from a human host. Such fusions result in the production of hybridoma cell lines secreting human monoclonal antibodies reactive with epitopes of interest. Such monoclonal antibodies are useful in the same way as prior art monoclonal antibodies with the added advantage of being less likely to induce adverse reactions in humans receiving monoclonal antibody therapy. The prior art is replete with examples of the therapeutic use of monoclonal antibodies. The present invention additionally provides methods for the production of hybridoma cell lines secreting human monoclonal antibodies reactive with epitopes of interest. The subject mouse/human heterohybrid cell line EL41 was deposited for patent purposes on May 16, 1990 with the European Collection of Animal Cell Cultures and given Accession No. 90051602.
Patients will be scored with Patient-Oriented Eczema Measure (POEM), Eczema Area and Severity Index (EASI), SCORAD (SCORing Atopic Dermatitis) and Dermatology Life Quality Index (DLQI) to assess disease severity. The investigators will measure trans epidermal water loss (TEWL), take bacterial swabs for analysis of the microbiome and culture for Staphylococcus aureus and test for mutations in the filaggrin-gene by sputum samples. Blood serum samples will be taken to measure serum (s) -Immunoglobulin E, s-vitamin D status, full blood count including white cell differential and different cytokines. Any history of allergic asthma, allergic rhinitis or food allergy will be noted as well as any recent history of sun exposure, use of tanning beds or UVB-therapy.

The suberythemal dose of UVB for each patient will be established. In each patient two contralateral areas (e.g. both underarms) with eczema will be chosen, which are as similar as possible regarding distribution and severity. One area will be biopsied with a 4mm punch followed by locally treatment with nb-UVB (311nm) three times. In this way the untreated side will serve as an internal control. Both sides will be biopsied after these initial three rounds of treatment. The patients will then undergo 24 standard full-body nb-UV-treatment sessions followed by a new biopsy of the same area. Skin from non-lesional sun-protected skin from nates will also be samples prior to and after UVB-treatment.
The invention discloses a therapeutic hepatitis B vaccine. Active components of the therapeutic hepatitis B vaccine comprise a protein gp96, a hepatitis B surface antigen and a hepatitis B core protein. The protein gp96 has a sequence shown in the sequence 1 of the sequence table. The hepatitis B surface antigen has a sequence shown in the sequence 5 of the sequence table. The hepatitis B core protein has a sequence shown in the sequence 3 of the sequence table. The active components also comprise a plasmid pcDNA-gp96 containing a coding gene of the protein gp96, a plasmid pcDNA-HB containing a coding gene of the hepatitis B surface antigen and a plasmid pcDNA-HBc containing a coding gene of the hepatitis B core protein. The therapeutic hepatitis B vaccine provided by the invention can effectively inhibit hepatitis B virus (HBV) replication, can eliminate viruses infecting the liver and has a very important value to hepatitis B prevention and treatment.
Qualitative semi-structured interviews to explore approaches taken to regimes, including one case study group regarding the Public Benefit and Privacy Panel in Scotland. No use of drugs and no personal health related interventions. Same approaches taken to 3 other case study groups which do not involve health.
Bupivacaine hydrochloride injection contains bupivacaine hydrochloride, an amide local anesthetic, as the active pharmaceutical ingredient. The route of administration for bupivacaine hydrochloride injection is by injection, for infiltration, perineural, caudal, epidural, or retrobulbar use. [see Warnings and Precautions (5.4)].

Bupivacaine hydrochloride is 2-piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate. It is a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula:

Bupivacaine hydrochloride injection is a clear and colorless sterile isotonic solution. Each mL of multiple-dose vial contains 2.5 mg, 5 mg of bupivacaine hydrochloride (equivalent to 2.22 mg, 4.44 mg of bupivacaine, respectively), sodium chloride for isotonicity, sodium hydroxide or hydrochloric acid to adjust the pH between 4 and 6.5 in water for injection.

For the Multiple-dose vials, each mL also contains 1 mg methylparaben as preservative.
The present invention is an electrochemical test strip for biochemical detection including a substrate, a circuit layer, testing reagent and plural resistance elements. The substrate includes a reading section and a detection section, and a detection channel is formed on the surface of the detection section. The circuit layer is disposed on the substrate and includes plural metal circuits and plural electrodes. The metal circuits extends from the reading section to the detection section. The electrodes are located in the detection channel. The testing reagent covers the electrodes. Each of the resistance elements is placed across the adjacent two metal circuits and is electrically connected thereto to achieve the purpose of identifying electrochemical test strips.